TOKYO -- Japanese pharmaceutical companies are increasingly investing in China, India and other Asian markets outside their home country where lifestyle-related diseases are taking hold.
The companies mostly plan to market drugs that have lost patent protection in Japan. Although less costly generic versions of these drugs are becoming popular, the companies expect Asia's growing income levels to fuel demand.
